The role and therapeutic targeting of IL-6 in rheumatoid arthritis (RA). The prospects for future applications, new therapeutic strategies of IL-6 targeting therapy and relevant issues with regard to the clinical management of IL-6 blockade in RA are discussed. PubMed, Expert Rev Clin Immunol, 2017 Jun;13(6):535-551. (Also see Causes of Rheumatoid Arthritis and Interleukins)
Genomics, transcriptomics and proteomics to elucidate the pathogenesis of rheumatoid arthritis. This review examines how recent advances in the fields of genomics, transcriptomics and proteomics have contributed to our understanding of rheumatoid arthritis. PubMed, Rheumatol Int, 05/10/2017. (Also see Causes of Rheumatoid Arthritis)
Response to Treatment with TNFa Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of Granulocyte–macrophage colony–stimulating factor (GM-CSF) and GM-CSF+ T Lymphocytes. The use of biomarker signatures of distinct pro-inflammatory pathways could lead to evidence-based prescription of the most appropriate biological therapies for different RA patients. PubMed, Clin Rev Allergy Immunol, 05/09/2017. (Also see Treatments for Rheumatoid Arthritis and Biologic Agents)
A quantitative method for the assessment of dysarthrophonia in myasthenia gravis (MG). This study demonstrates that non–invasive physiological methods (electroglottography and speech acoustics) offer essential tools for the assessment of dysarthrophonia in MG patients. PubMed, J Neurol Sci, 2017 Jun 15;377:42-46. (Also see Myasthenia Gravis)
Neuropsychological performance in patients with myasthenia gravis. Neuropsychological performance declines in patients with myasthenia gravis: attention was more affected than other cognitive areas. PubMed, Medicina (B Aires), 2017;77(2):117-120. (Also see Myasthenia Gravis)
Azathioprine (AZA) Maintenance Therapy to Prevent Relapses in Autoimmune Pancreatitis (AIP). AZA is an effective and safe treatment to prevent AIP relapses. PubMed, Clin Transl Gastroenterol, 2017 Apr 27;8(4):e90. (Also see Pancreatitis, Autoimmune and Immunosuppressants)
Chronic fatigue syndrome and the immune system: Where are we now? In this review, we will discuss the potential of different components of the immune system to be involved in the pathogenesis of myalgic encephalomyelitis/chronic fatigue syndrome. PubMed, Neurophysiol Clin, 2017 Apr;47(2):131-138. (Also see Chronic Fatigue Syndrome)
The treatment of fatigue by non–invasive brain stimulation (NIBS). Fatigue is a commonly observed symptom in the field of potentially treatable pathologies by NIBS, yet very little data has been published regarding its treatment. PubMed, Neurophysiol Clin, 2017 Apr;47(2):173-184. (Also see Fatigue)
Fibromyalgia in Behçet's disease: a narrative review. PVD is a rare complication of BD and management of immunosuppressive agents may improve the prognosis and should be recommended. PubMed, Br J Pain, 2017 May;11(2):97-101. (Also see Behçet's Disease and Fibromyalgia)
Clinical analysis of Behçet's disease(BD) associated with pulmonary vascular disease (PVD). PVD is a rare complication of BD and management of immunosuppressive agents may improve the prognosis and should be recommended. PubMed, Zhonghua Jie He He Hu Xi Za Zhi, 2017 May 12;40(5):343-348. (Also see Behçet's Disease)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: